Glionova is dedicated to the development of innovative therapies for difficult-to-treat cancers using the company’s unique expertise and proprietary technology.

Our lead product, GLN-1001, is being developed for treating patients suffering from glioblastoma (GBM), the most common and most aggressive primary brain tumor. GBM is a devastating disease with marginal life expectancy and limited treatment options, necessitating the development of conceptually new therapeutic strategies.

Kategorier: Pharma

Gå till Glionovas hemsida